Loading
A phase 2 trial of Azacitidine, Romidepsin, Belinostat, Pralatrexate and Gemcitabine in Peripheral T-cell lymphomas, run by University of Virginia, now recruiting.
Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL is a phase 2 interventional study registered as NCT04747236 by University of Virginia, with 50 participants planned, started 2021-02-19 and due to reach its primary completion in 2028-06-02. Interventions recorded: Azacytidine, Romidepsin, Belinostat, Pralatrexate, Gemcitabine. Conditions recorded: PTCL.
Linked to the drug Romidepsin because the registry names it among its interventions and Peripheral T-cell lymphomas among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Belinostat, Pralatrexate, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Romidepsin and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Romidepsin and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Azacitidine and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/